Sanofi Long Term Debt 2010-2023 | SNY

Sanofi long term debt from 2010 to 2023. Long term debt can be defined as the sum of all long term debt fields.
  • Sanofi long term debt for the quarter ending December 31, 2023 was $15.528B, a 0.8% decline year-over-year.
  • Sanofi long term debt for 2023 was $15.528B, a 0.8% decline from 2022.
  • Sanofi long term debt for 2022 was $15.653B, a 22.73% decline from 2021.
  • Sanofi long term debt for 2021 was $20.258B, a 10.18% decline from 2020.
Sanofi Annual Long Term Debt
(Millions of US $)
2023 $15,528
2022 $15,653
2021 $20,258
2020 $22,555
2019 $22,547
2018 $25,990
2017 $16,193
2016 $18,607
2015 $14,566
2014 $17,648
2013 $13,833
2012 $13,786
2011 $17,409
2010 $8,890
2009 $8,313
Sanofi Quarterly Long Term Debt
(Millions of US $)
2023-12-31 $15,528
2023-09-30
2023-06-30 $15,528
2023-03-31
2022-12-31 $15,653
2022-09-30
2022-06-30 $16,965
2022-03-31
2021-09-30
2021-03-31
2020-09-30
2020-03-31
2019-09-30
2019-03-31
2018-03-31
2017-12-31 $16,193
2017-09-30
2017-06-30 $16,708
2017-03-31
2016-12-31 $18,607
2016-09-30
2016-06-30 $16,775
2016-03-31
2015-09-30
2015-06-30 $11,914
2014-06-30 $13,873
2013-06-30 $13,959
2012-06-30 $13,198
2012-03-31
2011-12-31 $17,409
2011-09-30
2011-06-30 $19,122
2011-03-31
2010-12-31 $8,890
2010-09-30
2010-06-30 $9,009
2010-03-31
2009-12-31 $8,313
2009-09-30
2009-06-30 $9,512
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $123.116B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Innoviva (INVA) United States $0.998B 7.01